ArticleDiscover oncology2025
Multi-omics highlights the impacts of cryptorchidism history on immune microenvironment variation in TGCT.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundThe unique altered biological processes in testicular germ cell tumor (TGCT) patients with cryptorchidism history require further investigation and the accumulation of tumor-related features in cryptorchidism remains unclear. MATERIALS AND
methodsWe analyzed transcriptome and DNA methylation (DNAme) data from normal, undescended testis (UDT), and TGCT samples. Clustering, pseudo temporal trajectory analysis, and functional annotation of differentially methylated probes (DMPs) and differentially expressed genes (DEGs) were performed. Protein-protein interaction (PPI) networks were constructed for DEGs affected by DMPs. Weighted gene co-expression network analysis (WGCNA) identified genes related to cryptorchidism history. Single-cell RNA sequencing (scRNA-seq) assessed hub gene expression differences at cellular level across tissues.
resultsTranscriptome and DNAme analyses showed immune-related changes in TGCT samples, with increased immune infiltration and involvement of developmental pathways in cases with cryptorchidism history. WGCNA highlighted hub genes, with IFI16 and PLEKHG6 showing increased expression from normal to UDT and TGCT, whereas WDR60, LIPE, and F3 were predominantly expressed in normal tissues. ScRNA-seq analysis revealed the expression of hub genes primarily in spermatogenic and immune-related cell types. Public transcriptome from pediatric UDT samples demonstrated their similarities to tumor, with developmental and immune-related changes. Nevertheless, adult UDT samples exhibited fewer DNAme alterations than TGCT samples, with DNAme profiles resembling normal tissues and lacking tumor-related changes. The molecular pathways and characteristics of pediatric and adult UDT were distinct.
conclusionsWe revealed unique molecular pathways in TGCT samples with cryptorchidism history and identified tumor-related features in cryptorchidism accumulation. Cryptorchidism history significantly remodels the immune microenvironment of TGCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.